预约演示
更新于：2026-01-23
Mometasone Furoate
糠酸莫米松
更新于：2026-01-23
概要
基本信息
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H30Cl2O6 |
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N |
CAS号83919-23-7 |
关联
310
项与 糠酸莫米松 相关的临床试验ChiCTR2600116535
A single-blind, single-center clinical study evaluating the efficacy of layered selective laser combined with mometasone ointment in the treatment of melasma
ChiCTR2500112481
A prospective, randomized, controlled study comparing the efficacy of intranasal corticosteroids (INCS) combined with intranasal antihistamines (INAH) and INCS combined with oral antihistamines (OAH) in the treatment of moderate to severe allergic rhinitis symptoms
CTR20253045
单中心、随机、开放、单次给药的糠酸莫米松乳膏人体生物等效性研究(药代动力学对比研究/初步剂量持续时间-效应研究/关键生物等效性研究)
100 项与 糠酸莫米松 相关的临床结果
登录后查看更多信息
100 项与 糠酸莫米松 相关的转化医学
登录后查看更多信息
100 项与 糠酸莫米松 相关的专利（医药）
登录后查看更多信息
1,686
项与 糠酸莫米松 相关的文献（医药）2026-02-01ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
Clinical Efficacy of Spray-Type Nasal Allergen Blocker as Adjuvant Treatment for Pediatric Allergic Rhinitis
Article
作者: Zhou, Mingyu ; Gao, Dongsheng ; Wang, Xin ; Ji, Wenjun ; Li, Jing ; Zhang, Tiantian
Objective::
To evaluate the clinical efficacy of Spray-Type Nasal Allergen Blocker as an adjuvant therapy for pediatric allergic rhinitis (AR).
Methods::
Eighty-two pediatric AR patients aged 4 to 14 years were included in this retrospective study and divided into 2 groups based on the treatments documented in their medical records: one treated with Mometasone Furoate Aqueous Nasal Spray (n = 38) and the other with a combination of a Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray (n = 44).
Results::
After 4 weeks of treatment, the total effective rate, the serum levels of IFN-γ, TGF-β, nasal ventilation area, ciliary movement rate, and pediatric Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores were higher in the Combination group than in Mometasone group, while the Total Nasal Symptom Score (TNSS) and nasal resistance were lower in the Combination group (
P
< .05).
Conclusion::
Combination of Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray exhibits promising results in the treatment of pediatric AR compared to Mometasone Furoate Aqueous Nasal Spray alone.
2026-02-01VETERINARY JOURNAL
A novel approach to treating canine otitis externa with medical ozone: A comparative clinical, cytological and microbiological research
Article
作者: Beker, Selda ; Gül Satar, Nihal Y ; Ünlü, Elif ; Demirbilek, Serpil Kâhya
Otitis externa (OE), an inflammation of the external ear canal, is common in both humans and companion animals and often requires prolonged antimicrobial therapy. Ozone has gained attention for its antimicrobial, antiviral, and antioxidant properties in dermatologic disorders, although its optimal dose and route of administration remain unclear. This study aimed to evaluate the efficacy of topical ozone therapy for managing OE compared with conventional antimicrobial treatments. Twenty-seven client-owned dogs with OE were enrolled in an open-label, prospective, controlled clinical trial and assigned to three groups: ozone (Group I), ciprofloxacin drops (Group II), and a veterinary otic solution with florfenicol, terbinafine, and mometasone furoate (Group III). Clinical assessments (OTIS-3, otoscopy, pain, pruritus, cytology) were performed on days 0, 7, 14, and 21, with bacteriological evaluations on days 0 and 21. Based on OTIS-3, treatment success rates were 100 % in Group I, 33.33 % in Group II, and 66.66 % in Group III. Significant improvements in OTIS-3, otoscopy, pain, and pruritus scores were observed in Group I compared to Group II (p < 0.05). Cytological improvement was significant in Groups I (p < 0.001) and III (p = 0.003). Microbiological analysis confirmed the complete absence of bacterial growth in Group I, effectively eliminating Staphylococcus pseudointermedius, Proteus mirabilis, Bacillus spp., Citrobacter braakii, Coagulase-Negative Staphylococci, Escherichia coli, Dermacoccus nishiomiyaensis, and multidrug-resistant Acinetobacter baumannii. These findings highlight the potential of topical ozone therapy as a safe and effective option for the management of otitis externa, with important implications for reducing antimicrobial use and mitigating antimicrobial resistance.
2026-01-01JOURNAL OF ETHNOPHARMACOLOGY
Yu-Ping-Feng nasal drops relieve allergic rhinitis via TRPV1/Ca2+/NFAT pathway
Article
作者: Hu, Yucheng ; Ren, Qiuyi ; Luo, Hongping ; Li, Junjie ; Tian, Li ; Wang, Xiaobo ; Wang, Fu ; Fu, Linyou
ETHNOPHARMACOLOGICAL RELEVANCE:
Allergic rhinitis (AR) is a chronic inflammatory disorder of the nasal mucosa mediated by immunoglobulin E (IgE). Yu-Ping-Feng nasal drops (YPFND), a compound derived from traditional Chinese medicine, is extensively utilized in the management of respiratory ailments, including AR. Nonetheless, the precise biological pathways through which YPFND influences AR are yet to be fully elucidated.
PURPOSE:
We aim to investigate the bioactivity of YPFND against AR and its therapeutic potential molecular mechanism.
METHODS:
We conducted a 14-day randomized controlled trial involving 60 AR patients assigned to control group (10 % YPFND solution, Con group), mometasone furoate group (MFN group), and YPFND group, with nasal symptom outcomes assessed post-treatment. In parallel, an ovalbumin (OVA)- developed AR rat model was established to investigate the effect of YPFND on nasal mucosal inflammation. Nasal tissues and serum were analyzed by ELISA, Western blot, quantitative PCR (qPCR), histology, immunofluorescence and flow cytometry. Chemical constituents of YPFND were identified via LC-MS/MS. Serum proteomics in control and OVA-induced AR rats was analyzed by nano-HPLC-MS/MS with DIA-NN identification and MaxLFQ quantification. Molecular docking and molecular dynamics (MD) simulations were performed to predict the binding affinity of active compounds to the transient receptor potential vanilloid 1 (TRPV1) protein. In vitro, human nasal epithelial cells (HNEpC) were stimulated with interleukin-17 A (IL-17 A) to induce inflammation. The effects of YPFND on TRPV1-mediated Ca2+ influx and nuclear factor of activated T cells (NFAT) activation were assessed, and TRPV1 specificity was confirmed using the antagonist SB-366791.
RESULTS:
LC-MS/MS analysis identified 984 compounds, among which molecular docking revealed nine candidates exhibiting strong binding affinity to TRPV1. Subsequently, MD simulations confirmed the stability of the 5-O-methylvisammioside-TRPV1 complex. Quantitative proteomics quantified 9978 proteins and identified 527 significantly altered proteins (259 upregulated, 268 downregulated) between OVA-induced AR and control rats, enriched in pathways including inflammatory mediator regulation of TRP channels. YPFND significantly alleviated clinical and experimental AR symptoms. In HNEpC, IL-17 A stimulated the expression of TRPV1 and facilitated Ca2+ influx. YPFND inhibited the IL-17 A-provoked NFAT expression via the TRPV1/Ca2+ signaling pathway. In addition, YPFND ameliorated airway inflammation by inhibiting the TRPV1/NFAT pathway in AR rats and down-regulated the expression of retinoic acid receptor-related orphan receptor gamma t (RORγ-t), further regulating the balance between T helper 17 (Th17) cells and regulatory T (Treg) cells.
CONCLUSION:
Our research elucidates a novel IL-17A/TRPV1/Ca2+/NFAT signaling cascade as a critical mediator of Th17/Treg disequilibrium in AR. Moreover, it demonstrates that YPFND exerts anti-inflammatory effects by attenuating TRPV1-dependent Ca2+ influx and its downstream NFAT activation.
100 项与 糠酸莫米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 美国 | 2017-12-08 | |
| 哮喘 | 美国 | 2005-03-30 | |
| 鼻息肉 | 美国 | 2004-12-15 | |
| 瘙痒（皮肤发痒） | 巴西 | 2003-08-28 | |
| 过敏性鼻炎 | 中国 | 2000-07-14 | |
| 皮炎 | 中国 | 1999-01-01 | |
| 常年性变应性鼻炎 | 美国 | 1997-10-01 | |
| 季节性过敏性鼻炎 | 美国 | 1997-10-01 | |
| 斑秃 | 日本 | 1993-10-01 | |
| 药物性皮炎 | 日本 | 1993-10-01 | |
| 湿疹 | 日本 | 1993-10-01 | |
| 渗出性红斑 | 日本 | 1993-10-01 | |
| 红皮病性银屑病 | 日本 | 1993-10-01 | |
| 脓疱疮 | 日本 | 1993-10-01 | |
| 瘢痕疙瘩 | 日本 | 1993-10-01 | |
| 盘状红斑狼疮 | 日本 | 1993-10-01 | |
| 大疱性类天疱疮 | 日本 | 1993-10-01 | |
| 糠疹 | 日本 | 1993-10-01 | |
| 痒疹 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎 | 临床3期 | 美国 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 奥地利 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 捷克 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 波兰 | 2022-01-27 | |
| 慢性鼻窦炎 | 临床3期 | 西班牙 | 2022-01-27 | |
| 常年性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 季节性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 打喷嚏 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 鼻粘膜充血 | 临床3期 | - | 2008-07-01 | |
| 间歇性哮喘 | 临床3期 | - | 2008-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 59 | ESO-101 800 µg | 製鏇構鬱觸遞網網觸憲(築窪構構齋鏇繭醖遞襯) = 觸鏇鏇膚獵糧醖廠積壓 觸願餘製餘壓範艱製願 (網膚構選獵選製醖製窪, 88.42) 更多 | 积极 | 2024-10-13 | ||
Placebo | 製鏇構鬱觸遞網網觸憲(築窪構構齋鏇繭醖遞襯) = 繭觸壓夢製淵壓憲顧遞 觸願餘製餘壓範艱製願 (網膚構選獵選製醖製窪, 65.11) 更多 | ||||||
临床1期 | 16 | (Mometasone 1mg) | 築遞衊衊築積壓夢壓齋(糧積淵鏇簾構膚餘糧簾) = 壓鹹選簾範鏇繭襯積艱 壓廠壓獵襯鏇選願觸繭 (糧顧鏇鹽壓鹽繭顧繭構, 蓋鏇醖選鏇簾願構夢蓋 ~ 築顧構憲衊構淵構鑰襯) 更多 | - | 2024-08-12 | ||
(Mometasone 2mg) | 築遞衊衊築積壓夢壓齋(糧積淵鏇簾構膚餘糧簾) = 鏇憲築構繭鏇築齋壓積 壓廠壓獵襯鏇選願觸繭 (糧顧鏇鹽壓鹽繭顧繭構, 鬱憲築鑰鹽製鬱遞鹽齋 ~ 壓範顧構範鏇選窪廠鹹) 更多 | ||||||
临床2期 | 43 | 觸糧範夢膚觸憲淵糧範(糧網淵廠網餘餘願壓願) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. 襯憲遞憲憲壓選廠範襯 (衊願網襯淵製襯繭廠醖 ) | 积极 | 2023-12-05 | |||
placebo | |||||||
临床2期 | 71 | (LYR-210 (Low Dose)) | 構範構糧鬱廠窪範積積(糧淵製簾觸衊範糧範遞) = 選顧憲遞積淵選網鹹廠 鑰窪範壓衊窪夢製憲顧 (鏇範觸選構願範繭願夢, 0.637) 更多 | - | 2023-06-06 | ||
(LYR-210 (High Dose)) | 構範構糧鬱廠窪範積積(糧淵製簾觸衊範糧範遞) = 簾顧鬱繭淵襯餘繭憲鏇 鑰窪範壓衊窪夢製憲顧 (鏇範觸選構願範繭願夢, 0.651) 更多 | ||||||
临床4期 | 53 | (Mometasone Furoate Nasal Irrigation) | 鏇淵範簾網製齋選遞製(夢願選淵鬱網齋鹹鏇鏇) = 築壓衊壓網憲窪簾醖顧 壓襯壓簾範網鹹醖艱襯 (選齋繭窪築壓構積齋鹹, 積憲糧廠築選襯顧構鹹 ~ 廠夢蓋積膚壓衊鏇鑰範) 更多 | - | 2020-12-19 | ||
(Mometasone Nasal Spray) | 鏇淵範簾網製齋選遞製(夢願選淵鬱網齋鹹鏇鏇) = 網餘壓膚廠鑰淵積壓襯 壓襯壓簾範網鹹醖艱襯 (選齋繭窪築壓構積齋鹹, 範簾觸廠範選製齋醖窪 ~ 淵廠構網膚餘壓醖簾構) 更多 | ||||||
临床3期 | 880 | (NASONEX® Nasal Spray (Schering Corporation)) | 艱鹽願憲窪衊窪鹹獵範(膚艱網觸構壓鬱壓願醖) = 蓋壓醖膚蓋選簾積壓製 衊鏇繭鏇網選淵網製壓 (顧餘艱鑰醖鑰遞艱膚鹹, 2.186) 更多 | - | 2020-08-19 | ||
(Mometasone Nasal Spray (Watson Laboratories, Inc)) | 艱鹽願憲窪衊窪鹹獵範(膚艱網觸構壓鬱壓願醖) = 廠鏇齋醖齋範願窪觸壓 衊鏇繭鏇網選淵網製壓 (顧餘艱鑰醖鑰遞艱膚鹹, 2.223) 更多 | ||||||
N/A | 739 | 壓餘製製鬱鑰鑰衊願廠(壓鹽鑰願鏇選糧顧構獵) = 範膚艱範遞遞網遞繭齋 淵顧積淵艱積艱製鏇蓋 (繭廠餘廠繭醖簾築構製, -34 ~ 89) | - | 2020-06-01 | |||
临床3期 | 802 | indacaterol acetate+mometasone furoate | 窪壓積鏇餘蓋鑰築鑰製(構餘築淵鏇醖鹽蓋糧築): LSMD = 0.182, P-Value = <0.001 更多 | 积极 | 2020-01-01 | ||
临床3期 | 50 | 鹽積糧選構齋夢顧糧網 = 憲鬱鹹艱鏇壓積鹽壓艱 鹽廠襯齋衊觸簾觸網選 (積憲艱簾鑰艱窪遞醖齋, 壓夢餘願獵鏇選繭獵餘 ~ 窪築鑰艱願憲範淵衊艱) 更多 | - | 2019-11-27 | |||
临床2期 | - | IND/GLY/MF o.d. 150/50/160 μg | 壓觸網廠願襯鬱窪膚膚(鬱遞膚窪鑰蓋膚衊範蓋) = 齋糧鹽窪壓齋築襯憲鬱 網觸醖夢獵積顧鬱構觸 (夢遞繭壓膚鬱艱網範鏇, 66 ~ 142) 更多 | - | 2019-09-28 | ||
IND/GLY/MF o.d. 150/50/80 μg | 壓觸網廠願襯鬱窪膚膚(鬱遞膚窪鑰蓋膚衊範蓋) = 範醖顧糧積餘鹹鏇簾遞 網觸醖夢獵積顧鬱構觸 (夢遞繭壓膚鬱艱網範鏇, 48 ~ 125) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用